387 results on '"Wege, Henning"'
Search Results
2. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial
3. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
4. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
5. EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
6. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
7. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
8. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
9. OS-027-YI Immune checkpoint profiles on circulating extracellular vesicles predict response to immunotherapy in heptaocellular carcinoma
10. Differenzialtherapie bei fortgeschrittenen Gallengangskarzinomen
11. Management von benignen Leberherden
12. Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023
13. Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023
14. Pancreatic, Hepatic, and Biliary Tract Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023
15. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion
16. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
17. Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas
18. Gallengangskrebs: Zu häufig eine zu späte Diagnose
19. 68/m mit zunehmender Schwäche bei bekannter Hepatitis C: Vorbereitung auf die Facharztprüfung: Fall 10
20. 43/m mit zunehmender Schwäche bei bekannter Gallengangsklerose: Vorbereitung auf die Facharztprüfung: Fall 17
21. Assessing the impact of COVID-19 on liver cancer management (CERO-19)
22. Tumoren der extrahepatischen Gallenwege
23. Autoreninnen und Autoren
24. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
25. NASH limits anti-tumour surveillance in immunotherapy-treated HCC
26. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
27. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion
28. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
29. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
30. Autoren
31. Maligne Tumoren der Gallengänge und der Gallenblase
32. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
33. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
34. Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma—correlation with liver cancer and liver cirrhosis
35. Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
36. Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab
37. The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab
38. Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study
39. Dynamic evolution of the serum metabolome reflects human hepatocarcinogenesis
40. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction
41. Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile
42. Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report
43. Kapitel 41 - Maligne Tumoren der Gallengänge und der Gallenblase
44. Kapitel 68 - Maligne Tumoren der Gallengänge und der Gallenblase
45. Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia
46. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis
47. Supplementary Figure 2 from Forced Activation of β-Catenin Signaling Supports the Transformation of hTERT-Immortalized Human Fetal Hepatocytes
48. Supplementary Figure 1 from Forced Activation of β-Catenin Signaling Supports the Transformation of hTERT-Immortalized Human Fetal Hepatocytes
49. Supplementary Figure 4 from Forced Activation of β-Catenin Signaling Supports the Transformation of hTERT-Immortalized Human Fetal Hepatocytes
50. Supplementary Figure 3 from Forced Activation of β-Catenin Signaling Supports the Transformation of hTERT-Immortalized Human Fetal Hepatocytes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.